Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 302, Issue 1, 2002, Pages 205-211

  Hoffman, Sandra J ^a,c   Vasko Moser, Janice ^a   Miller, William H ^a,b   Lark, Michael W ^c   Gowen, Maxine ^a   Stroup, George ^a  

^a Departments of Musculoskeletal Diseases   (United States)

^b Department of Medicinal Chemistry ^*  (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 8 [2 [6 (METHYLAMINO) 2 PYRIDINYL]ETHOXY] 3 OXO 2 (2,2,2 TRIFLUOROETHYL) 1H 2 BENZAZEPINE 4 ACETIC ACID; DEOXYPYRIDINOLINE; ESTRADIOL; SB 273005; THYROXINE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VITRONECTIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; FOLLOW UP; HORMONE INHIBITION; HYPERTHYROIDISM; METABOLIC BONE DISEASE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RAT; URINALYSIS;

AMINO ACIDS; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; MALE; OSTEOCALCIN; PYRIDINES; RATS; RECEPTORS, VITRONECTIN; THYROXINE; TRIIODOTHYRONINE;

EID: 0036085353     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.302.1.205     Document Type: Article

References (36)

1. Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture
2. Antibody to β3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat
3. Monitoring individual response to hormone replacement therapy with bone markers
4. 3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo
5. Trabecular bone remodeling and bone balance in hyperthyroidism
6. Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein
7. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis
8. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis
9. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers
10. Integrins on rat osteoclasts: Characterization of two monoclonal antibodies (F4 and F11) to rat beta 3
11. Effect of thyroid hormone on bone and mineral metabolism in rat: Evaluation by biochemical markers
12. Antiresorptive therapy in hyperthyroid patients: Longitudinal changes in bone and mineral metabolism
13. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women
14. A rat model of thyroid hormone-induced bone loss: Effect of antiresorptive agents on regional bone density and osteocalcin gene expression
15. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: The effect of calcium and calcitonin
16. Antagonism of the osteoclast vitronectin receptor with an orally active non-peptide inhibitor prevents cancellous bone loss in the ovariectomized rat
17. Effects of alendronate on bone loss in pre- and post-menopausal hyperthyroid women treated with methimazole
18. The early effects of radioiodine therapy for hyperthyroidism on biochemical indices of bone turnover
19. Bony manifestations of thyrotoxicosis
20. The discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic
21. Effects of thyroid hormones on bone and mineral metabolism
22. Biochemical characterization of human osteoclast integrins: Osteoclasts express alpha v beta 3, alpha 2 beta 1 and alpha v beta 1 integrins
23. Etidronate inhibits the thyroid hormone-induced bone loss in rats assessed by bone mineral density and messenger ribonucleic acid markers of osteoblast and osteoclast function
24. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women
25. Thyroid hormones and mineral metabolism
26. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women
27. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism
28. 5 is expressed on avian osteoclast precursors and regulated by retinoic acid
29. Expression of alpha v and beta 3 integrin subunits in rat osteoclasts in situ
30. A longitudinal study of markers of bone turnover in Graves' disease and their value in predicting bone mineral density
31. Accelerated bone degradation in thyroid carcinoma patients during thyroxine treatment, measured by determination of the carboxyterminal telopeptide region of type I collagen in serum
32. Effect of hyperthyroidism and its treatment on bone mineral content
33. Hip fractures and the thyroid: A case-control study
34. Direct demonstration of inhibitory effect of echistatin on PTH-induced bone resorption in vivo in mice
35. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats
36. The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats